Lièvre Astrid, Laurent Valérie, Cudennec Tristan, Peschaud Frédérique, Malafosse Robert, Benoist Stéphane, Penna Christophe, Lepère Céline, Vaillant Jean-Nicolas, Julié Catherine, Teillet Laurent, Nordlinger Bernard, Rougier Philippe, Mitry Emmanuel
Institut Curie, René Huguenin Hospital, Department of Medical Oncology, Saint-Cloud, France; University of Versailles Saint Quentin, Faculty of Health Sciences, Montigny-Le-Bretonneux, France.
AP-HP, Kremblin-Bicêtre Hospital, Department of Hepato-Gastroenterology and Digestive Oncology, Le Kremlin Bicêtre, France.
Dig Liver Dis. 2014 Sep;46(9):838-45. doi: 10.1016/j.dld.2014.05.005. Epub 2014 Jun 5.
Few data are available on management of very elderly colon cancer patients, especially concerning the parameters of therapeutic decisions and the role of geriatricians.
We retrospectively reviewed the charts of patients over 80 years of age who underwent surgery for a localised colon cancer in a French academic hospital.
A total of 176 patients underwent surgery (postoperative morbidity and mortality rates: 25% and 6.7%). Adjuvant chemotherapy was discussed at a multidisciplinary team meeting for 91% of stage III patients, but only 13.5% of them were treated. Twenty-five patients relapsed: 19 were discussed at the multidisciplinary meeting and 16 were treated (5 had a metastasectomy). Despite their increase with time, geriatric assessments were infrequent, 17% (33% after 2006), and had no impact on postoperative morbi-mortality. Median overall survival and recurrence-free survival were 65.3 months and 65.1 months, respectively. Age, emergency surgery, and Charlson comorbidity index were independent prognostic factors.
Selected elderly colon cancer patients have significant access to surgery. However, postoperative morbi-mortality rates remain high and adjuvant chemotherapy rarely prescribed. Perioperative geriatric assessment, especially before surgery, should be routinely proposed to these patients to evaluate its impact on postoperative morbi-mortality and prescription of adjuvant treatment.
关于高龄结肠癌患者的管理,尤其是治疗决策参数和老年病医生的作用,可用数据很少。
我们回顾性分析了在一家法国学术医院接受局部结肠癌手术的80岁以上患者的病历。
共有176例患者接受了手术(术后发病率和死亡率分别为25%和6.7%)。91%的Ⅲ期患者在多学科团队会议上讨论了辅助化疗,但其中只有13.5%接受了治疗。25例患者复发:19例在多学科会议上进行了讨论,16例接受了治疗(5例进行了转移灶切除术)。尽管随着时间推移老年评估有所增加,但仍不常见,为17%(2006年后为33%),且对术后发病率和死亡率没有影响。总生存期中位数和无复发生存期中位数分别为65.3个月和65.1个月。年龄、急诊手术和查尔森合并症指数是独立的预后因素。
部分老年结肠癌患者有机会接受手术。然而,术后发病率和死亡率仍然很高,辅助化疗很少使用。应常规对这些患者进行围手术期老年评估,尤其是在手术前,以评估其对术后发病率、死亡率及辅助治疗处方的影响。